Foley Hoag Congratulates Predictive Biosciences on Series C Financing
Boston,
MA -
June 16, 2010 -
Foley Hoag LLP congratulates its client Predictive Biosciences, Inc. on the closing of a $25 million Series C preferred stock financing. Predictive, a commercial stage, fully-integrated developer of novel molecular diagnostic cancer assays and a provider of anatomic pathology laboratory products and services, will use the proceeds of the financing to complete multi-center clinical trials for Predictive’s CertNDx bladder cancer assay and support its commercial launch.
Lawyers in FoleyHoag’s Life Sciences group have represented Predictive Biosciences since December 2006. The transaction team consisted of Jeffrey Quillen, partner and co-chair of the firm’s Life Sciences practice, and associates Joel Needleman, Michelle Limaj and Patrick Connolly.
For the full company press release, click here.
About Foley Hoag LLP
Foley Hoag is a dynamic law firm that represents public and private clients in a wide range of disputes and transactions worldwide. We have expertise in industries such as life sciences and healthcare, technology, energy and renewables, investment management, and professional services. We also offer our clients market-leading international litigation and arbitration and corporate social responsibility services. From our offices in Boston, Washington, D.C. and Paris, and our Emerging Enterprise Center in Waltham, Massachusetts, we provide strategic legal advice that is tailored to each of our client’s unique goals. Foley Hoag combines powerful regional, national and international practices that share a common emphasis on client service. We are focused on what we do best: helping our clients succeed through the delivery of exceptional legal service. For more information, visit www.foleyhoag.com.